Display options
Cite
Díaz-Zaragoza M, Hernández-Ávila R, Ostoa-Saloma P. Recognition of tumor antigens in 4T1 cells by natural IgM from three strains of mice with different susceptibilities to spontaneous breast cancer. Oncol Lett. 2016;13(1):271-274doi: 10.3892/ol.2016.5427.
Díaz-Zaragoza, M., Hernández-Ávila, R., & Ostoa-Saloma, P. (2017). Recognition of tumor antigens in 4T1 cells by natural IgM from three strains of mice with different susceptibilities to spontaneous breast cancer. Oncology letters, 13(1), 271-274. https://doi.org/10.3892/ol.2016.5427
Díaz-Zaragoza, Mariana, et al. "Recognition of tumor antigens in 4T1 cells by natural IgM from three strains of mice with different susceptibilities to spontaneous breast cancer." Oncology letters vol. 13,1 (2017): 271-274. doi: https://doi.org/10.3892/ol.2016.5427
Díaz-Zaragoza M, Hernández-Ávila R, Ostoa-Saloma P. Recognition of tumor antigens in 4T1 cells by natural IgM from three strains of mice with different susceptibilities to spontaneous breast cancer. Oncol Lett. 2017 Jan;13(1):271-274. doi: 10.3892/ol.2016.5427. Epub 2016 Nov 23. PMID: 28123554; PMCID: PMC5244975.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Jan;13(1):271-274. doi: 10.3892/ol.2016.5427. Epub 2016 Nov 23.

Recognition of tumor antigens in 4T1 cells by natural IgM from three strains of mice with different susceptibilities to spontaneous breast cancer.

Oncology letters

Mariana Díaz-Zaragoza, Ricardo Hernández-Ávila, Pedro Ostoa-Saloma

Affiliations

  1. Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, 04510 Ciudad de México, México.

PMID: 28123554 PMCID: PMC5244975 DOI: 10.3892/ol.2016.5427

Abstract

The issue of antibody responses to tumors is potentially important to cancer immunologists. Early detection of cancer represents one of the most promising approaches to reduce the growing cancer burden. Natural immunoglobulin (Ig)M antibodies have been associated with the recognition and elimination of cancerous and precancerous cells. Using natural IgM antibodies, the present study identified a set of antigens in healthy mice from three different strains and examined whether the global patterns of antibodies are able to discriminate between a condition of more or less susceptibility to breast cancer. The current study performed two-dimensional (2D) immunoblotting to detect antigens from 4T1 cells using natural IgM from serum of healthy female mice from three different strains. The t-test was used to analyze the total number of spots. There were no significant differences in the numbers of antigens recognized in each strain. However, differences in patterns were observed on 2D immunoblots among the three strains. The reactivity patterns of natural IgM antibodies to particular antigens exhibited non-random clustering, which discriminated between strains with different susceptibilities to spontaneous breast cancer. The results demonstrated that the patterns of reactivity to defined subsets of antigens are able to provide information regarding differential diagnosis associated with breast cancer sensitivity. Therefore, it may be concluded that it is possible to segregate the IgM humoral immune response toward cancer antigens according to the genetic background of individuals. In addition, it is possible to identify the recognized antigens that allow grouping or discriminate between the different IgM antibodies expressed. The possible association between a particular antigen and cancer susceptibility requires further study, but the methodology exposed in the present study may identify potential candidates for this possible association.

Keywords: 4T1 cells; breast cancer; immunoglobulin M; mice strains; two-dimensional immunoblot

References

  1. Oncol Rep. 2015 Sep;34(3):1106-14 - PubMed
  2. Clin Cancer Res. 2009 Jul 15;15(14):4733-41 - PubMed
  3. J Proteome Res. 2008 Apr;7(4):1388-94 - PubMed
  4. Immunol Rev. 2008 Apr;222:328-40 - PubMed
  5. J Proteome Res. 2005 Jul-Aug;4(4):1123-33 - PubMed
  6. Immunobiology. 2015 Sep;220(9):1050-8 - PubMed
  7. N Engl J Med. 2005 Sep 22;353(12):1288-90 - PubMed
  8. Eur J Immunol. 1993 Nov;23(11):2851-9 - PubMed
  9. Expert Rev Anticancer Ther. 2006 Aug;6(8):1215-23 - PubMed
  10. Cancer Cell Int. 2014 Jan 28;14(1):9 - PubMed
  11. FEBS J. 2009 Dec;276(23):6880-904 - PubMed
  12. Ann N Y Acad Sci. 1963 Nov 4;108:805-31 - PubMed
  13. N Biotechnol. 2009 Jun;25(5):294-8 - PubMed
  14. J Proteome Res. 2008 Apr;7(4):1490-9 - PubMed
  15. Cancer Biomark. 2010;6(5-6):247-56 - PubMed

Publication Types